What is the recommended dose and duration of fosfomycin (Fosfomycin tromethamine) for treating uncomplicated urinary tract infections (UTIs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fosfomycin Dosing for Uncomplicated UTI

For uncomplicated cystitis in women, administer a single 3-gram oral dose of fosfomycin tromethamine, which is the FDA-approved regimen and provides therapeutic urinary concentrations for 24-48 hours. 1, 2

Standard Dosing Regimen

  • The recommended dose is one 3-gram sachet of fosfomycin tromethamine granules mixed with water, taken as a single dose for women 18 years and older with uncomplicated UTI (acute cystitis). 2

  • This single-dose regimen is specifically recommended by the European Association of Urology and the American Urological Association as a first-line therapy option (Grade B evidence). 1

  • The medication may be taken with or without food, but must always be mixed with water before ingesting—never take in dry form. 2

Duration and Follow-Up

  • Duration is a single dose only for uncomplicated cystitis—no repeat dosing is needed for standard uncomplicated UTI. 1, 2

  • The single dose provides therapeutic urinary concentrations for 24-48 hours, with some studies showing activity for up to 2-4 days. 1, 3

  • Routine post-treatment urinalysis or urine cultures are not indicated for asymptomatic patients. 1

  • If symptoms do not resolve by the end of treatment or recur within 2 weeks, obtain urine culture and antimicrobial susceptibility testing. 1

Important Clinical Limitations

  • Fosfomycin is FDA-approved and guideline-recommended ONLY for uncomplicated cystitis in women—it should not be used for pyelonephritis, complicated UTIs, or routinely in men due to insufficient efficacy data. 1, 4

  • The European Association of Urology explicitly does not recommend fosfomycin for routine use in men with UTIs due to limited clinical efficacy data in this population. 4

  • For complicated UTIs with systemic symptoms (including male UTIs), guidelines recommend combination therapy with beta-lactam/aminoglycoside combinations or third-generation cephalosporins for 7-14 days. 4

Special Populations

  • Pregnancy: Fosfomycin is safe in pregnancy and recommended by European Urology guidelines for asymptomatic bacteriuria in pregnant women as standard short-course treatment or single-dose administration. 1, 3

  • For multidrug-resistant pathogens (ESBL-producing organisms, VRE, MRSA) causing uncomplicated UTI, the same single 3-gram oral dose is recommended. 1

Common Pitfall to Avoid

Do not use multi-dose regimens (3 grams every 48-72 hours for 3 doses) for uncomplicated UTI—this regimen has been studied for complicated lower UTI in patients who failed other therapies or have MDR pathogens 5, 6, but the FDA-approved and guideline-recommended regimen for uncomplicated UTI remains a single dose only. 1, 2

Adverse Effects

  • The most commonly reported adverse events are diarrhea, nausea, and vomiting, occurring in approximately 4-6% of patients. 1, 5

  • Gastrointestinal disturbances and skin rash may occur but are generally mild. 1

  • Fosfomycin has minimal propensity for collateral damage to intestinal flora compared to other antibiotics. 1

References

Guideline

Fosfomycin Treatment for Uncomplicated Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Fosfomycin Use in Male Patients with UTIs

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.